论文部分内容阅读
目的探讨脑微出血(CMB)对脑卒中溶栓预后的影响。方法选取2015年5月至2016年5月64例脑卒中溶栓治疗患者作为研究对象,依据脑微出血将其分为研究组(n=32)与对照组(n=32),研究组合并脑微出血,对照组无脑微出血症状,对比分析两组治疗前脑微出血分布情况、治疗后无症状性颅内出血率及症状性颅内出血率、新发脑微出血率、生存率。结果研究组腔隙性脑梗死例数明显多于对照组,且2型糖尿病、高脂血症发病率显著高于对照组(P<0.05);治疗后,两组无症状性颅内出血率、生存率对比差异未见统计学意义(P>0.05);研究组症状性颅内出血率、新发脑微出血率明显高于对照组(P<0.05)。结论对卒中患者给予溶栓临床治疗时,脑微出血为主要危险因素,可提高患者新发脑微出血以及症状性颅内出血机率,对溶栓预后产生不良影响。
Objective To investigate the effect of cerebral microbleeding (CMB) on the prognosis of stroke after thrombolysis. Methods Sixty-four patients with thrombolytic stroke in our hospital from May 2015 to May 2016 were divided into study group (n = 32) and control group (n = 32) according to cerebral micro-hemorrhage. The study group Cerebral hemorrhage and cerebral hemorrhage without cerebral hemorrhage in the control group. The distribution of hemorrhage in the forebrain in the two groups was compared and analyzed. Asymptomatic intracranial hemorrhage and symptomatic intracranial hemorrhage, new hemorrhage and survival rate were compared between the two groups. Results The incidence of lacunar infarction was significantly higher in the study group than in the control group, and the incidence of type 2 diabetes mellitus and hyperlipidemia was significantly higher than that of the control group (P <0.05). After treatment, the rates of asymptomatic intracranial hemorrhage, There was no significant difference in survival rate between the two groups (P> 0.05). Symptomatic intracranial hemorrhage rate and neonatal cerebral hemorrhage rate in the study group were significantly higher than those in the control group (P <0.05). Conclusion Cerebral micro-hemorrhage is the main risk factor for thrombolytic therapy in patients with stroke, which can improve the rate of new-onset cerebral hemorrhage and symptomatic intracranial hemorrhage and adversely affect the prognosis of thrombolysis.